Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out more about the effects of an investigational
combination of medicines, which includes special immune cells (T-cells).
A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood
cell that protect the body from viral infections, help other cells fight bacterial and fungal
infections, produce antibodies, fight cancers, and coordinate the activities of other cells
in the immune system.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute